CCX9588 / Amgen - LARVOL DELTA

Small Molecule Antagonist of C-C Chemokine Receptor 1 (CCR1) Reduces Disc Inflammation in the Rabbit Model. (PubMed, Spine J) - "Our pre-clinical studies demonstrate that CCR1 and CCR2 antagonist delivery through intradiscal injection is sufficient to reduce disc inflammation at early time points, while CCR1 antagonists had longer term anti-inflammatory effects. Clinical studies have found that CCR1 antagonist was safe, tolerable and clinically active in reducing inflammation in rheumatoid arthritis patients. These studies suggest that CCR1 antagonist may be a promising biological treatment to reduce disc inflammation that translates to back pain relief."

Journal • Preclinical • Back Pain • Immunology • Pain • Rheumatoid Arthritis • Rheumatology • CXCL8 • MRI